TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01653587

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
Study: NCT03680833

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel node detection in cervical cancer
Description: The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
Study: NCT04314245

Intervention type: OTHER
Intervention: Active Comparator: Pathology
Description: Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.

Intervention type: OTHER
Intervention: Active Comparator: Pathology
Description: Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.

Intervention type: OTHER
Intervention: Active Comparator: Clinical Diagnosis
Description: Routine clinical diagnosis and treatment of benign disease of the urinary system

Intervention type: OTHER
Intervention: Active Comparator: Clinical diagnosis
Description: Routine urine test and imaging diagnostic techniques, such as B-ultrasound.

Intervention type: OTHER
Intervention: Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay
Description: A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.

Intervention type: OTHER
Intervention: Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay
Description: A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.

Intervention type: OTHER
Intervention: Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay
Description: A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.

Intervention type: OTHER
Intervention: Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay
Description: A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.
Study: NCT04311268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F2D armband
Description: Comparison of the core temperature obtained during 24-48 h with eCelsius and with F2D armband in different life situations.
Study: NCT01628523

Intervention type: OTHER
Intervention: For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.
Description: Mechanical ventilation via an endotracheal tube or tracheostomy tube
Study: NCT04732442

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: Impact Oral® Nestle, Switzerland

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Standard Oral Nutritional Support
Description: Fortimel Compact Protein® Nutricia, United Kingdom
Study: NCT02626156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling gel pack
Description: Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cooling cotton pack
Description: Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
Study: NCT01804257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Health Feedback System
Description: The digital health offering passively collects and records medication-taking behavior and other habits of daily living
Study: NCT03579693

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CoQ10
Description: CoQ10 tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide riboside
Description: NR tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill designed to mimic coQ10 and NR
Study: NCT02472587

Intervention type: OTHER
Intervention: Questionnaire
Study: NCT02517255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging
Description: 7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
Study: NCT00069134

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sulfur amino acids
Description: Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sulfur amino acids
Description: Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
Study: NCT01055717

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Avenanthramide-enriched oats
Description: Single dose, 24 hour pharmacokinetic trial

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avenanthramide-enriched oats
Description: Single dose, 24 hour pharmacokinetic trial
Study: NCT01623167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: hATG, CsA, EPAG Day 14 to Month 6
Description: hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: hATG, CsA, EPAG Day 14 to Month 3
Description: hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6
Description: hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extension Cohort
Description: Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
Study: NCT00751959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curosurf
Description: Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curosurf
Description: Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
Study: NCT02528942

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be given to study patients.
Study: NCT06192472

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical sclerotherapy
Description: Sclerosant will be retained within the vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical sclerotherapy
Description: Sclerosant will be retained within the vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical sclerotherapy
Description: Sclerosant will be retained within the vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical sclerotherapy
Description: Sclerosant will be retained within the vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Sodium Tetradecyl Sulphate
Description: 1% Sodium Tetradecyl Sulphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Tetradecyl Sulphate
Description: 3% Sodium Tetradecyl Sulphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Polidocanol
Description: 0.5% Polidocanol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Polidcanol
Description: 3% Polidcanol
Study: NCT02317198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor or Prasugrel
Study: NCT02705612

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Study: NCT04078529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 day falls prevention training
Description: Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise programme
Description: A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise programme
Description: A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Environmental Assessment
Description: Use of the Homefast assessment tool to reduce risk of falls at home.
Study: NCT02705612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Internal Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Study: NCT03900728

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy with needles
Description: Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy with beads
Description: A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo Adhesive disks
Description: Single-use adhesive disks without needles or beads.
Study: NCT03825640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE
Description: Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
Study: NCT02252640

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP (5 x 10^10 vp)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd63 ME-TRAP (5 x 10^10 vp)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA ME-TRAP (2 x 10^8 pfu)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA ME-TRAP (2 x 10^8 pfu)
Study: NCT01430143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Daily exercise for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Daily exercise for 12 weeks.
Study: NCT00906178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CyberSenga
Description: Internet-based HIV prevention program
Study: NCT02501148

Intervention type: DEVICE
Intervention: carotid artery stenting
Description: Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
Study: NCT01721486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO acetaminophen
Description: PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
Study: NCT01178476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyposafe Hypoglycaemia alarm device
Description: An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyposafe Hypoglycaemia alarm device
Description: An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
Study: NCT02030769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pronase
Description: use pronase to improve visibility during endoscopical iodine staining
Study: NCT04078529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Assessment
Description: Use of the Homefast assessment tool to reduce risk of falls at home.
Study: NCT02030769

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
Study: NCT03926949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition
Description: Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Nutrition Care
Description: Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
Study: NCT00582712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Description: Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
Study: NCT01501890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroxyprogesterone caproate
Description: 250mg once a week by intramuscular administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study: NCT01693497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogical exposure therapy
Description: This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
Study: NCT01465880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Part A
Description: Smoking abstinence, smoking 2 and 4 cigarettes
Study: NCT03700840

Intervention type: DEVICE
Group type: OTHER
Intervention: Interdental brushes
Description: interdental brush at 4 sites and PCR analysis
Study: NCT00263432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human allogenic chondrocytes
Description: Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
Study: NCT03583359

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiesse (+)
Description: Radiesse (+) for jawlines.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse (+)
Description: Radiesse (+) for jawlines.
Study: NCT01415583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 0.5mg/kg (max dose 20mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 0.5mg/kg (max dose 20mg)
Study: NCT02764359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV vancomycin
Description: IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV vancomycin
Description: IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
Study: NCT01027559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
Study: NCT01970241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH
Description: NPH given per study table based on steroid dose and patient weight in kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Correction Factor
Description: Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Correction Factor
Description: Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
Study: NCT04700085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReMotion Knee
Description: The ReMotion Knee is a prosthetic knee mostly used in low-income countries. It has been approved according to the ISO 10328 standards and has received the CE Mark.
Study: NCT02672189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVA-Online
Description: Internet-based cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVA-Online
Description: Internet-based cognitive behavioral therapy
Study: NCT02874534

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Treatment
Description: Treatment will consist of 15 weekly 45-minute sessions.
Study: NCT04175899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist-led Oral Chemo Care Program (POCCP)
Description: Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients.
Study: NCT00829634

Intervention type: DRUG
Group type: OTHER
Intervention: l-methamphetamine
Description: 5mg of l-methamphetamine per day throughout the 2 week study

Intervention type: DRUG
Group type: OTHER
Intervention: d-methamphetamine
Description: 15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13